No products in the cart
Adipotide Peptide (FTPP) and its Metabolic Properties
What Is Adipotide (FTPP)?
Adipotide, previously known as Prohibitin-TP01, is a synthetically made proapoptotic peptide that performs a unique function. It targets and kills all types of fat cells. It reduces the number of fat cells by reducing the blood supply to these adipocytes. Adipotide targets proteins present on the walls of the blood vessels supplying the adipocytes. This process helps interfere with and disrupt the blood supply to fat cells. It ultimately results in the fat cells getting reabsorbed and metabolized.
Research has shown that Adipotide FTPP targets only the blood vessels supplying the fat cells while sparing all the other blood vessels supplying the various organs and tissues in the body.
Research conducted on monkeys has shown that not only does adipotide aid in weight loss, but it also has some effect on insulin sensitivity. It can play a role in the management of type 2 diabetes.
Potential Role Of Adipotide (FTPP) In Weight Loss
In 2011, research began on adipotide to see whether it has a profound effect on weight loss or not. Phase 1 clinical trials on the Rhesus monkey showed that the administration of adipotide resulted in a targeted and highly selective apoptosis of the blood vessels supplying the adipocytes of white fat. This process resulted in the ischemic death of the affected adipocytes. The loss of these fat cells caused significant weight loss. This weight loss was linked with a decreased body mass index or BMI. It resulted in improved insulin sensitivity.
Researchers also observed an interesting side effect. Treatment with adipotide reduced weight by fat loss and reduced the overall food consumption in the test animals. That is, adipotide also helps reduce appetite and results in weight loss.
The selectivity of adipotide in targeting the vasculature of only fat cells is due to the presence of a protein receptor called Prohibitin. Prohibitin is only present in the vasculature of fat and cancer cells. Adipotide interacts with this particular protein to induce white adipocyte apoptosis.
The sustenance of cancer cells depends on their vast blood supply. One of the approaches that can be used in anti-cancer treatments is targeting cancer cells’ blood supply. Disrupting the blood supply might aid in eventually killing these cancer cells. The protein receptor prohibitin is present on the walls of the blood vessels supplying cancer cells. Since adipotide is associated with prohibitin to bring about apoptosis, there is a chance that it can target cancer cells and lead to their death by ischemia.
Since prohibitin is only very selectively present in cancer and fat cells, adipotide in anti-cancer treatment can produce positive results. Advanced studies show that adipotide kills only the cancer cells while protecting the surrounding cells and tissues.
Improved Glucose Tolerance Via Adipotide (FTPP)
The term glucose tolerance generally refers to the body’s response to glucose levels higher than usual. A test called OGTT or the oral glucose tolerance test measures this response. A set amount of considerably high glucose is administered in this test, and the blood glucose levels are measured. If the result is higher than average, it becomes a significant finding. This test is somewhat diagnostic of diabetes, and if the result is significantly higher than average, the person has a great tendency to become diabetic.
Adipotide may bring about significant weight loss by burning white adipocytes. While this effect brings about a change in body mass index, this is not its only result. Research suggests that white fat loss is directly associated with improved insulin sensitivity. In a nutshell, adipotide causes a decline in fatty cells and can lead to fat loss.
Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.